DekaBank Deutsche Girozentrale Purchases 805 Shares of Illumina, Inc. (NASDAQ:ILMN)

DekaBank Deutsche Girozentrale grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.8% during the first quarter, HoldingsChannel reports. The institutional investor owned 102,049 shares of the life sciences company’s stock after purchasing an additional 805 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Illumina were worth $13,969,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. WCM Investment Management LLC boosted its stake in Illumina by 2,232.3% during the 1st quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock valued at $463,760,000 after purchasing an additional 3,232,418 shares during the last quarter. Capital World Investors purchased a new position in Illumina in the 4th quarter worth about $271,753,000. Norges Bank bought a new position in Illumina during the 4th quarter valued at about $264,636,000. Coatue Management LLC purchased a new stake in shares of Illumina during the 4th quarter valued at about $119,285,000. Finally, Findlay Park Partners LLP bought a new stake in shares of Illumina in the first quarter worth approximately $100,120,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ILMN shares. Royal Bank of Canada dropped their target price on shares of Illumina from $249.00 to $242.00 and set an “outperform” rating on the stock in a report on Monday, July 1st. TD Cowen dropped their target price on Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research report on Thursday, June 6th. Jefferies Financial Group began coverage on shares of Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. StockNews.com initiated coverage on shares of Illumina in a report on Sunday, June 30th. They issued a “buy” rating on the stock. Finally, Barclays boosted their price target on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus price target of $158.57.

Illumina Price Performance

Shares of NASDAQ:ILMN traded down $4.65 during mid-day trading on Friday, reaching $117.70. The stock had a trading volume of 1,824,098 shares, compared to its average volume of 1,642,188. The business’s 50 day moving average price is $111.29 and its 200 day moving average price is $123.67. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $195.64. The company has a market cap of $18.75 billion, a P/E ratio of -14.44 and a beta of 1.15. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the firm earned $0.08 EPS. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 1.5 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.